At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 43 enrolled
Drug / intervention
Enzalutamide and Dutasteride or finasteridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Enzalutamide Plus Dutasteride/Finasteride as First Line Treatment for Vulnerable Patients ≥ 65 Years With Systemic Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Enzalutamide and Dutasteride or finasteride for Prostate Cancer. Completed, enrolled 43 participants across 2 sites.
Detailed Summary
Determine the effect of enzalutamide and dutasteride or finasteride on the time to prostatic-specific antigen level increase in patients age 65 or older.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartSep 2014
Primary CompletionOct 2023
TodayJul 2026
First PostedAug 11, 2014
Enrollment StartSep 1, 2014
Primary CompletionOct 31, 2023
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 11.9 years ago
Interventions
Enzalutamide and Dutasteride or finasteridedrug
Use of either two oral drugs together 1. Enzalutamide by mouth daily and dutasteride by mouth daily or 2. Enzalutamide by mouth daily and finasteride by mouth daily